2,958 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Oxbow Advisors LLC

Oxbow Advisors LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 2,958 shares of the company’s stock, valued at approximately $230,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Martin Investment Management LLC grew its holdings in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after purchasing an additional 7,615 shares during the period. Integrated Advisors Network LLC increased its holdings in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the period. Creative Planning grew its holdings in AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after acquiring an additional 16,692 shares during the period. TD Asset Management Inc grew its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after buying an additional 121,876 shares during the period. Finally, Northcape Wealth Management LLC bought a new position in AstraZeneca in the 2nd quarter valued at about $269,000. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, TD Cowen increased their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 0.3 %

AZN opened at $64.49 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The company’s 50 day simple moving average is $77.07 and its two-hundred day simple moving average is $78.56. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market capitalization of $199.96 billion, a price-to-earnings ratio of 31.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.